Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol

Medical Care

Volumn 37, Issue 7, 1999, Pages 678-691

  Tunis, Sandra L ^a,b   Croghan, Thomas W ^e   Heilman, Douglas K ^d   Johnstone, Bryan M ^a,c   Obenchain, Robert L ^a,d  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c INDIANA UNIVERSITY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Lilly Corporate Center ^*

Author keywords

Antipsychotic; Health; Olanzapine; SF 36, schizophrenia; Validity

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIRENZEPINE;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DAILY LIFE ACTIVITY; DISCRIMINANT ANALYSIS; ECONOMICS; FACTORIAL ANALYSIS; FEMALE; HEALTH SURVEY; HUMAN; MALE; MIDDLE AGED; PSYCHOMETRY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SCHIZOPHRENIA; STANDARD; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DISCRIMINANT ANALYSIS; FACTOR ANALYSIS, STATISTICAL; FEMALE; HALOPERIDOL; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; PSYCHOMETRICS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0033163192     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-199907000-00008     Document Type: Article

References (59)

1. Carpenter WT, Buchanan RW. Schizophrenia. N Engl J Med 1994;330:681-90.
2. Fenton WS. Longitudinal course and outcome of schizophrenia. In: Moscarelli M, Rupp A, Sartorius N, eds. Handbook of Mental Health Economics and Health Policy. New York: John Wiley and Sons, 1996:79-91.
3. Hall RC, Gardner ER, Popkin MK, LeCann AF, Stickney SK. Unrecognized physical illness prompting psychiatric admission: A prospective study. Am J Psychiatr 1981;138:629.
4. Hegarty, JD, Baldessarini, RJ, Tohen, M, Waternaux, C, Oepen, G. One hundred years of schizophrenia: A meta-analysis of the outcomes literature. Am J Psychiatr 1994;151:1409-16.
5. Jeste DV, Akiko J, Lindamer LA, Lacro JP. Medical comorbidity in schizophrenia. Schizophren Bull 1996;22:413-30.
6. Josiassen RC, Schindler B. Medical comorbidity and schizophrenia: Editor's introduction. Schizophren Bull 1996;22:411-2.
7. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DMS-III-R psychiatric disorders in the United States. Results for the National Comorbidity Study. Arch Gen Psychiatry 1994;138:629.
8. Sewell DD. Schizophrenia and HTV. Schizophren Bull 1996;22:465-73.
9. Kane JM. Schizophrenia. N Engl J Med 1993;334:34-41.
10. Andreason NC, Olsen S. Negative v positive schizophrenia: Definition and validation. Arch Gen Psychiatr 1982;39:789-94.
11. Andreason NC. Symptoms, signs, and diagnosis of schizophrenia. Lancet 1995;346:477-81.
12. Tollefson GD, Beasley Jr. CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatr 1997;154:457-65.
13. Vieweg V, Pandurangi A, Levenson J, Silverman J. Medical disorders in the schizophrenic patient. Int J Psychiatr Med 1995;25:137-72.
14. Beasley Jr. CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23.
15. Beasley Jr. CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996;124:159-67.
16. Lieberman JA. Atypical antipsychotic drugs as a first line treatment of schizophrenia: A rationale and hypothesis. J Clin Psychiatr 1996;(suppl 11):68-71.
17. Tollefson GD, Sanger TM. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatr 1997;154:466-74.
18. Ware JE, Jr. The status of health assessment 1994. Annu Rev Public Health 1995;16:327-54.
19. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophren Bull 1993;19:609-18.
20. Dickey B, Wagenaar H, Stewart A. Using Health Status Measures with the Seriously Mentally 111 in Health Services Research. Med Care 1996;34:112-6.
21. Russo J, Trujillo CA, Wingerson D, Decker K, Ries R, Wetzler H, et al. The MOS 36-item Short Form Health Survey. Reliability, validity, and preliminary findings in schizophrenic outpatients. Brief Report. Med Care 1998;36:752-6.
22. Stewart AL, Hays RD, Ware JE. Health perceptions, energy/fatigue, and health distress measures. In: Stewart AL, Ware JE, eds. Measuring Functioning and Well-Being. Durham, NC: Duke University, 1992:143-72.
23. Ware JE, Jr, Sherbourne CD. The MOS 36-item short form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
24. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center, 1993.
25. Ware JE, Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of the SF-36 Health Profile and summary Measure: Summary of Results from the Medical Outcomes Study. Med Care 1995;33:AS264-79.
26. McHorney CM, Ware JE, Lu JFR, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66.
27. McHorney CA, Ware JE, Raczek A. The MOS 36-item Short-Form Health Survey (SF-36):II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
28. th Annual Meeting of the Association for Health Services Research. Chicago, II: June 15-17, 1997.
29. Wolinsky FD, Stump TE. A measurement model of the Medical Outcomes Study 36-item Short-Form Health Survey in a clinical sample of disadvantaged, older, Black, and white men and women. Med Care 1996;34:537-48.
30. American Psychiatric Association. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders. 3rd ed., revised. Washington, DC: The Association, 1987.
31. Heinrichs, DW, Hanlon, TE, Carpenter, WT, Jr. The Quality of Life scale: An instrument for rating the schizophrenic deficit syndrome. Schizophren Bull 1984;10:388-98.
32. Hays RD, Marshall GN, Wang EYI, Sherbourne CD. Four-Year Cross-Lagged Associations Between Physical and Mental Health in the Medical Outcomes Study. J Consult Clin Psychol 1994;62:441-9.
33. Hays RD, Stewart AL. The structure of self-reported health in chronic disease patients. Psychol Assess 1990;2:22.
34. SAS Institute Inc., SAS/STAT User's Guide, Version 6, Fourth Edition, Vol. 1, Cary, NC: SAS Institute Inc., 1989.
35. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
36. Overall JE, Gorham DR.2 The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24:97-8.
37. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Publication ADM 76-338. Washington, DC: U.S. Department of Health, Education, and Welfare, 1976.
38. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. B J Psychiatr 1979;134:382-9.
39. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale. A procedure for measuring the overall severity of psychiatric disturbance. Arch Gen Psychiatr 1976;33:766-71.
40. International Resource Center for Health Care Assessment. Revised Multitrait Analysis Program Software (MAP-R). Boston, MA: The Health Institute, Division of Health Improvement, New England Medical Center, 1991.
41. Hays RD, Hayashi T, Carson S, Ware JE. User's Guide for the Multitrait Analysis Program (MAP). Santa Monica, CA: RAND, N-2786-RC, 1988.
42. Hays RD, Wang EYI. Multitrait Scaling Program: MULTI. Proceedings of the Seventeenth Annual SAS Users Group International Conference, 1992:1151-6.
43. Obenchain RL, Johnstone BM. Mixed model imputation of cost data for early discontinuers from a randomized clinical trial. Drug Info J 1999;33(1):191.
44. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-74.
45. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, NC: SAS Institute, 1996.
46. Tunis SL, Golbus MS, Copeland KL, Fine BA, Rosinsky BJ, Seely L. Normative scores and factor structure of the Profile of Mood States for women seeking prenatal diagnosis for advanced maternal age. Educ Psychol Measurement 1990;50:309-24.
47. Kim JO, Mueller CW. Factor analysis. Statistical Methods and Practical Issues. Beverly Hills: Sage Publications, 1988.
48. Nunnally J. Psychometric Theory. New York, NY: McGraw-Hill, 1978.
49. Nunnally JC, Berstein IH. Psychometric Theory. 3rd ed. New York: McGraw-Hill, 1994.
50. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297.
51. Dworkin RH. Pain insensitivity in schizophrenia: A neglected phenomenon and some implications. Schizophren Bull 1994;20:235-48.
52. Gierz M, Jeste DV. Physical comorbidity in elderly veterans affairs patients with schizophrenia and depression. Am J Ger Psychiatr 1993;1:165-70.
53. Carpenter WT, Strauss JS. The prediction of outcomes in schizophrenia IV: Eleven-year follow up of the Washington IPSS cohort. J Nerv Ment Dis 1991;179:517-25.
54. Carpenter WT, Buchanan RW. Schizophrenia. N Engl J Med 1994;330:681-90.
55. Lehman AF. Evaluating outcomes of treatments for persons with psychotic disorders. J Clin Psychiatr 1996;57(suppl 11):61-7.
56. Ioannidis JPA, Lau J. The impact of high-risk patients on the results of clinical trials. Clin Epidemiol 1997;50:1089-98.
57. Connelly JE, Philbrick JT, Smith GR, Jr., Kaiser DL, Wymer A. Health perceptions of primary care patients and the influence on health care utilization. Med Care 1989;27(suppl):S99-109.
58. Tunis SL, Croghan TW, Heilman DK, Johnstone BM, Obenchain RL. Changes in perceived physical and mental health status of a schizophrenia patient population following initiation of a conventional or an atypical antipsychotic medication. Poster presented at the 1998 American Psychiatric Association Meeting, Toronto. Ontario, Canada: May 30-June 4, 1998.
59. Van Putten T, May PRA. Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatr 1978;35:477-80.